Enobosarm

What is Enobosarm?

• Enobosarm, also known by its developmental code name GTx-024 and trade name Ostarine, is a selective androgen receptor modulator (SARM) that has gained attention for its potential therapeutic applications in muscle wasting conditions, osteoporosis, and other disorders.

Ostarine

Mechanism of Action

• Enobosarm functions by selectively binding to androgen receptors in tissues such as muscles and bones.
• Unlike traditional anabolic steroids, which can have a broad impact on various tissues including the prostate and liver, enobosarm's selective nature means it primarily targets androgen receptors in specific areas.
• Upon binding to these receptors, enobosarm modulates gene expression, promoting anabolic effects in muscle tissue and bone.
• This makes it a potential therapeutic agent for conditions involving muscle wasting, bone density loss, and frailty.

Ostarine

Medical Uses

• Enobosarm has been investigated for several potential medical uses:

2010-04-23 Ostarine vs Andarine

1. Muscle Wasting

• Enobosarm has shown promise in preventing and treating muscle wasting conditions, including those related to cancer, chronic obstructive pulmonary disease (COPD), and other chronic illnesses.
• By promoting muscle growth and preventing muscle loss, it may improve patients' quality of life and overall physical function.

2. Osteoporosis

• Research suggests that enobosarm may have a positive impact on bone health by increasing bone mineral density and reducing the risk of fractures.
• This potential makes it an intriguing option for osteoporosis treatment and prevention.

3. Hormone Replacement Therapy

• Enobosarm's selective androgen receptor modulation could potentially provide an alternative to traditional hormone replacement therapies for individuals with androgen deficiencies.

Clinical Trials

• Enobosarm has been studied extensively in clinical trials to assess its safety, efficacy, and potential benefits.
• Research has focused on various patient populations, including those with muscle wasting disorders and osteoporosis.
• Many trials have reported positive outcomes related to muscle mass, physical function, and bone health.
• However, it's important to note that enobosarm is still being researched, and further studies are needed to fully establish its safety profile and long-term effects.

Side Effects

• Enobosarm has generally shown a favorable safety profile in clinical trials.
• Reported side effects have been mild and include headache, back pain, and nausea.
• Additionally, because enobosarm is a SARM and not a traditional anabolic steroid, it may have a reduced risk of causing hormonal imbalances and related side effects.

Regulatory Status

• Enobosarm has not received full regulatory approval in many countries as of the current date.
• It is important to recognize that its development and regulatory status may vary by region.
• Some countries may permit its use in clinical trials, while others may not have approved it for any use.

Conclusion

• Enobosarm, as a selective androgen receptor modulator, holds promise for addressing muscle wasting, osteoporosis, and potentially other conditions.
• Its selective binding to androgen receptors offers the potential for therapeutic benefits with fewer side effects compared to traditional anabolic steroids.
• While research is ongoing and regulatory approvals are pending in some regions, enobosarm's potential applications in improving muscle health and bone density are of significant interest to the medical community.
• Continued research will provide a clearer understanding of its benefits and safety profile.

References

• Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):153-61. doi: 10.1007/s13539-011-0034-6. PMID: 22031847; PMCID: PMC3177038.
• Cilotti A, Falchetti A, Banti C, et al. Ostarine (GTx-024, MK-2866): a Selective Androgen Receptor Modulator (SARM) for treatment of muscle-wasting related to cancer, osteoporosis and aging. Report on the consensus meeting. Rome, 8-9 October 2015. J Endocrinol Invest. 2016 Feb;39(2):117-22. doi: 10.1007/s40618-015-0352-y. Epub 2016 Jan 8. PMID: 26738792.

• Dailymed label info on Enobosarm
• FDA Enobosarm

Enobosarm Resources
Latest articles Most recent articles Ongoing trials	Wikipedia